WTA SRY gene testing is now required for women’s eligibility on the WTA Tour, the association announced, with a one-time genetic screening requirement taking effect Tuesday.
The association said the screening will be conducted via routine DNA collection methods and that players must complete required documentation; refusal could expose a player to disciplinary action. Players who test negative for the SRY gene will be eligible to compete immediately, while positive results will lead to individualized medical assessment before any final eligibility decision is made, the WTA said.
WTA SRY gene testing policy: what it means for players
What the WTA changed
The WTA updated its women’s eligibility policy to require a one-time screening for the SRY gene, which is typically located on the Y chromosome and commonly associated with male-typical sex development. According to the association’s public summary, the test is intended to be a clear, administrable marker for eligibility in the women’s competition category.
Administratively, the policy requires documented consent: players must sign paperwork acknowledging the requirement. The association framed the change as replacing the previous testosterone-based standard with a genetic screen that the WTA says offers a definitive basis for classification. The policy is effective Tuesday, per the WTA announcement.
How SRY gene testing works
According to the WTA statement, samples for SRY gene analysis may be collected via cheek swab, blood draw or saliva sample. Laboratories then analyze DNA to detect the presence or absence of the SRY sequence. The WTA has said a detected SRY sequence does not automatically result in ineligibility; instead, a positive finding triggers a further clinical review so that decisions consider individual medical context.
Public details remain limited about the precise laboratory standards, permitted assays, chain-of-custody rules, data retention, or which accredited labs will be used. The WTA has said follow-up assessments will be medical and individualized, but it has not published full clinical protocols or the detailed timeline for those reviews.
Who is affected and immediate impact
The WTA’s public release stated that players who test negative for the SRY gene will be immediately eligible to participate in WTA events. The association also said, in its announcement, that it is not aware of any persons with male-typical sex development currently competing on the Tour. That attribution is to the WTA’s public statement and should not be read as an independent verification of roster composition.
The organization’s prior eligibility rule—updated in 2024—allowed athletes assigned male at birth who identify as female to compete in the women’s category if they maintained testosterone below a 2.5 nmol/L threshold for two years. The WTA says that standard is being replaced by the SRY gene screening requirement.
How this aligns with other sports
The WTA joins other federations that have moved toward sex-marker screening as part of eligibility rules. According to reported plans and recent federation announcements, World Athletics and World Boxing have implemented or proposed SRY screening for female-category entry, and the International Olympic Committee has discussed sex classification approaches ahead of the 2028 Games. Implementation details, legal frameworks and clinical thresholds differ substantially among bodies, and those descriptions are summaries of public reporting and federation statements rather than independent verification.
What comes next and procedural details
Under the WTA summary, a positive SRY result leads to further medical assessment before a final decision. The association said these reviews will be clinical and individualized, but the public notice did not specify the exact medical criteria, accredited laboratories, timelines for reviews, or the detailed appeals process for contested cases.
The policy specifies that refusing to submit to the required test could expose a player to disciplinary measures. However, the WTA’s public materials did not enumerate the specific sanctions, the steps in any adjudication or appeal procedures, or time limits for resolution. Those procedural gaps mean affected players and observers must rely on subsequent WTA guidance for complete operational details.
Privacy and medical considerations
The WTA said it aims to treat players with dignity and to implement the policy thoughtfully, but mandatory genetic screening raises privacy, medical and civil-rights concerns. Key unanswered questions include data-protection measures, who will have access to genetic results, how long results will be retained, and how the WTA will protect medical confidentiality. Commentary from medical and civil-rights observers has urged clarity on these points before broad implementation.
Background and context
Eligibility rules in women’s sport have evolved amid legal and scientific debate about fair competition, sex classification and inclusion. The shift from a testosterone-based rule to a genetic marker approach represents a significant change in the criteria used to determine eligibility at elite levels. Supporters argue such measures protect competitive fairness; critics warn of privacy intrusions and the need for clear, evidence-based medical standards.
FAQ
What is SRY gene testing?
SRY gene testing looks for the presence of the SRY sequence typically found on the Y chromosome; labs test DNA obtained from cheek swab, saliva or blood samples. The WTA describes the test as a one-time screening to establish women’s-category eligibility, with any positive result followed by further clinical evaluation.
Will current WTA players be tested?
The WTA’s policy requires a one-time screening for players seeking eligibility under the women’s category. The association stated in its announcement that players testing negative will be immediately eligible. The WTA also said it is not aware of any persons with male-typical development currently competing on the Tour; that phrasing is an attribution to the WTA rather than an independent roster audit.
What happens if an athlete refuses the test?
The WTA’s public summary indicates refusal could result in disciplinary action. The association has not published full details of what sanctions might apply or the exact appeals pathway in the event of contested outcomes; those procedural specifics remain to be clarified by follow-up WTA guidance.
Source attribution
This article is based on the WTA’s public announcement and reporting from news outlets. Official information referenced: the WTA’s news pages (https://www.wtatennis.com/news). Corroborating coverage includes the reporting linked here: https://www.foxnews.com/outkick-sports/wta-adopts-sry-gene-testing-protect-fair-competition-womens-professional-tennis. Additional federation context is drawn from public information on World Athletics (https://www.worldathletics.org/news) and the International Olympic Committee (https://olympics.com/ioc). Where the WTA’s public materials did not provide specific procedural details, this article notes that those items remain unclear pending further WTA guidance.
Reporting will be updated as the WTA publishes additional operational details, timelines or appeals procedures.
